The following information is being disclosed for the purposes of AIM rule 26
Description of the business
LiDCO researches, develops, manufactures and sells innovative medical devices, primarily for critical care and cardiovascular risk hospital patients who require real-time hemodynamic monitoring while undergoing major surgery, intensive care and cardiac procedures. LiDCO’s products provide critical hemodynamic data regarding the performance of a patient’s heart and effectiveness of the blood circulation in delivering oxygen to the body’s tissues.
Directors’ and Company Secretary’s Information
Peter Grant – Non-Executive Chairman
Matthew Sassone – Chief Executive Officer
Tim Hall – Chief Financial Officer
Phil Cooper – Non-Executive Director
James Wetrich – Non-Executive Director
Tim Hall – Company Secretary
For more information, please visit the Board page.
The board has three committees – Audit Committee, Remuneration Committee and Nominations Committee. For details of committee’s members, please see Principle 6 on the Corporate Governance page.
For more information and the Terms of Reference of the committees, please see Principle 9 on the Corporate Governance page.
For more information, please visit the Corporate Governance page.
The Company’s country of incorporation and main country of operation
LiDCO Group Plc is incorporated in the UK which is also its main country of operation.
For more information, please visit the Company Information page.
Current Articles of Association
The Company’s New Articles, adopted by special resolution passed on 1 June 2020, can be downloaded here here.
For more information, please visit the Shareholder Information page.
For more information, please visit the Annual & Interim Reports page.
Notifications and Documents sent to Shareholders
For regulatory announcements made by the Company, please visit the RNS page.
For the admission document, please visit the Admissions Document page.
For the circulars and similar publications sent to shareholders within the past 12 months, please visit the Shareholder Information page.
Takeovers and Mergers
The company is subject to the UK City Code on Takeovers and Mergers
For more information, please visit the Advisers page.
Page last up-dated: 2 June 2020